Search Results for keywords:"Schedule I"

The Drug Enforcement Administration (DEA) is proposing to place the substance 4-chloromethcathinone (4-CMC) in schedule I of the Controlled Substances Act. This move aims to impose strict regulations similar to other highly controlled drugs, as 4-CMC is known to have a high potential for abuse and no accepted medical use in the U.S. The decision also helps the United States comply with international agreements on psychotropic substances. Public comments on this proposal are accepted until January 29, 2025.

The Drug Enforcement Administration (DEA) has announced that Royal Beverages, LLC has applied to become a registered bulk manufacturer of marijuana, which is a Schedule I controlled substance. This registration would allow Royal Beverages, LLC, located in Harrisburg, Pennsylvania, to produce bulk active pharmaceutical ingredients (APIs) for research purposes. Comments or objections about this application can be submitted electronically through the Federal eRulemaking Portal before May 27, 2025. The DEA will evaluate the application based on certain legal regulations to ensure it complies with all laws and safeguards against illegal distribution.

The Drug Enforcement Administration (DEA) has announced that Ohana Bio Pharma, LLC has applied to be registered as a bulk manufacturer of controlled substances in schedule I, specifically for marihuana. This application is part of a program to grow marihuana for scientific and medical research. The DEA will evaluate the application according to its regulations to ensure legal compliance and prevent any misuse. Interested parties can submit their comments or objections by May 27, 2025, through the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) has announced that Cosmic Light LLC, located in Boulder, Colorado, has applied to become a registered bulk manufacturer of marihuana, classified as a Schedule I controlled substance. This registration would allow them to produce bulk materials needed to develop pharmaceutical products for research purposes. Interested parties have until April 30, 2021, to submit comments or objections regarding this application. The DEA will review this application following its established regulations to ensure compliance and prevent misuse.

The Drug Enforcement Administration (DEA) has received an application from AJC Industries, Inc. to become a registered bulk manufacturer of marihuana, a Schedule I controlled substance, for scientific and medical research. This notice allows current registered manufacturers and other applicants to submit comments or objections by April 26, 2021. The DEA will evaluate the application to ensure compliance with legal and regulatory standards and to prevent misuse. Interested parties need to reference Docket No. DEA-797 when submitting their feedback to the DEA's office in Springfield, Virginia.

The Drug Enforcement Administration (DEA) temporarily placed a substance called brorphine in Schedule I of the Controlled Substances Act due to its high potential for abuse, lack of accepted medical use, and potential danger to public safety. This action means strict regulatory controls are now in place regarding the manufacturing, distribution, and possession of brorphine. The DEA found brorphine on the illicit market in several countries and associated it with several fatalities in the U.S. Brorphine is a synthetic opioid with effects similar to fentanyl, which poses significant health risks and has been linked to the ongoing opioid epidemic. This temporary scheduling will last for two years and can be extended for an additional year.

The Drug Enforcement Administration (DEA) has announced that Livwell Michigan, LLC has applied to be registered as a bulk manufacturer of controlled substances, specifically marihuana, listed under Schedule I. The DEA will evaluate this application based on specific regulations and guidelines to ensure it complies with laws and has measures in place to prevent misuse. The public and other manufacturers have until April 26, 2021, to submit comments or objections regarding this application. If approved, Livwell Michigan, LLC would be allowed to produce marihuana for use in scientific and medical research, but not for other purposes.

The Drug Enforcement Administration (DEA) is extending the temporary Schedule I classification for seven specific fentanyl-related substances. This extension lasts for one year or until a permanent decision is made. These substances are considered a public safety hazard, and the DEA is working on permanently scheduling them. The temporary classification does not require the normal rulemaking processes, as the DEA needs to act quickly to prevent potential dangers.

The Drug Enforcement Administration proposes to make seven fentanyl-related substances permanently controlled under Schedule I of the Controlled Substances Act. These substances, identified as dangerous opioids, are currently regulated under a temporary order due to their potential for abuse and health hazards. If this proposal is finalized, it would enforce permanent restrictions and legal penalties on the handling of these substances, which include para-chlorofentanyl and ortho-chlorofentanyl. The public is encouraged to submit comments on this rule by January 29, 2025.